Top

Published in:

01-11-2018 | Original Article

Feasibility and accessibility of electronic patient-reported outcome measures using a smartphone during routine chemotherapy: a pilot study

Authors: Woo Kyun Bae, Jihyun Kwon, Hyun Woo Lee, Sang-Cheol Lee, Eun-Kee Song, Hyeok Shim, Keun Ho Ryu, Jemin Song, Sungbo Seo, Yaewon Yang, Jong-Hyock Park, Ki Hyeong Lee, Hye Sook Han

Published in: Supportive Care in Cancer | Issue 11/2018

Abstract

Purpose

There is growing interest in integrating electronic patient-reported outcome (PRO) measures into routine oncology practice for symptom monitoring. Here, we evaluated the feasibility and accessibility of electronic PRO measures using a smartphone (PRO-SMART) for cancer patients receiving routine chemotherapy.

Methods

The proposed PRO-SMART application obtains daily personal health record (PHR) data from cancer patients via a smartphone. An analysis report of cumulative PHR data is provided to the clinician in a format suitable for upload to electronic medical records (EMRs). Cancer outpatients who had received at least two cycles of chemotherapy and who were scheduled for two more cycles were enrolled.

Results

Between February 2015 and December 2016, 111 patients were screened and 101 of these were included. One-hundred patients used PRO-SMART at least once and were included in the final analysis (90.1% overall accessibility among all screened patients). The number of symptomatic adverse events (AEs) related to chemotherapy recorded in EMRs (mean ± standard deviation [SD]) increased from 0.92 ± 0.80 to 2.26 ± 1.80 (P < 0.001), and grading of AEs increased from 0.81 ± 0.69 to 1.00 ± 0.62 (P = 0.029). After using PRO-SMART, the numeric rating scale for pain (mean ± SD) increased from 0.20 ± 0.72 to 0.99 ± 1.55 (P < 0.001). A patient-reported questionnaire revealed that 64.2% of patients found it useful and 83% found it easy to use.

Conclusions

This study suggests that the proposed PRO-SMART is feasible and accessible for assessment of symptomatic AEs in cancer patients receiving chemotherapy for a prospective randomized trial.

Available only for authorised users

Siegel RL, Miller KD, Jemal A (2017) Cancer statistics, 2017. CA Cancer J Clin 67:7–30CrossRef

Jung KW, Won YJ, Oh CM, Kong HJ, Lee DH, Lee KH, Community of Population-Based Regional Cancer Registries (2017) Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2014. Cancer Res Treat 49:292–305CrossRef

Paessens BJ, von Schilling C, Berger K, Shlaen M, Müller-Thomas C, Bernard R, Peschel C, Ihbe-Heffinger A (2011) Health resource consumption and costs attributable to chemotherapy-induced toxicity in German routine hospital care in lymphoproliferative disorder and NSCLC patients. Ann Oncol 22:2310–2319CrossRef

McKenzie H, Hayes L, White K, Cox K, Fethney J, Boughton M, Dunn J (2011) Chemotherapy outpatients’ unplanned presentations to hospital: a retrospective study. Support Care Cancer 19:963–969CrossRef

National Cancer Institute, National Institutes of Health, US Department of Health and Human Services (2010) Common Terminology Criteria for Adverse Events (CTCAE), version 4. https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_40. Accessed 30 Dec 2014

Basch E, Iasonos A, McDonough T, Barz A, Culkin A, Kris MG, Scher HI, Schrag D (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7:903–909CrossRef

Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M, Appawu M, Iasonos A, Atkinson T, Goldfarb S, Culkin A, Kris MG, Schrag D (2009) Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst 101:1624–1632CrossRef

Basch E (2010) The missing voice of patients in drug-safety reporting. N Engl J Med 362:865–869CrossRef

Atkinson TM, Li Y, Coffey CW, Sit L, Shaw M, Lavene D, Bennett AV, Fruscione M, Rogak L, Hay J, Gönen M, Schrag D, Basch E (2012) Reliability of adverse symptom event reporting by clinicians. Qual Life Res 21:1159–1164CrossRef

10.

Di Maio M, Gallo C, Leighl NB, Piccirillo MC, Daniele G, Nuzzo F, Gridelli C, Gebbia V, Ciardiello F, De Placido S, Ceribelli A, Favaretto AG, de Matteis A, Feld R, Butts C, Bryce J, Signoriello S, Morabito A, Rocco G, Perrone F (2015) Symptomatic toxicities experienced during anticancer treatment: agreement between patient and physician reporting in three randomized trials. J Clin Oncol 33:910–915CrossRef

11.

Dueck AC, Mendoza TR, Mitchell SA, Reeve BB, Castro KM, Rogak LJ, Atkinson TM, Bennett AV, Denicoff AM, O'Mara AM, Li Y, Clauser SB, Bryant DM, Bearden JD 3rd, Gillis TA, Harness JK, Siegel RD, Paul DB, Cleeland CS, Schrag D, Sloan JA, Abernethy AP, Bruner DW, Minasian LM, Basch E, National Cancer Institute PRO-CTCAE Study Group (2015) Validity and reliability of the US National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). JAMA Oncol 1:1051–1059CrossRef

12.

Kotronoulas G, Kearney N, Maguire R, Harrow A, Di Domenico D, Croy S, MacGillivray S (2014) What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol 32:1480–1501CrossRef

13.

Atkinson TM, Ryan SJ, Bennett AV, Stover AM, Saracino RM, Rogak LJ, Jewell ST, Matsoukas K, Li Y, Basch E (2016) The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review. Support Care Cancer 24:3669–3676CrossRef

14.

Cleeland CS, Wang XS, Shi Q, Mendoza TR, Wright SL, Berry MD, Malveaux D, Shah PK, Gning I, Hofstetter WL, Putnam JB Jr, Vaporciyan AA (2011) Automated symptom alerts reduce postoperative symptom severity after cancer surgery: a randomized controlled clinical trial. J Clin Oncol 29:994–1000CrossRef

15.

Berry DL, Blumenstein BA, Halpenny B, Wolpin S, Fann JR, Austin-Seymour M, Bush N, Karras BT, Lober WB, McCorkle R (2011) Enhancing patient-provider communication with the electronic self-report assessment for cancer: a randomized trial. J Clin Oncol 29:1029–1035CrossRef

16.

Bennett AV, Jensen RE, Basch E (2012) Electronic patient-reported outcome systems in oncology clinical practice. CA Cancer J Clin 62:337–347CrossRef

17.

Jensen RE, Snyder CF, Abernethy AP, Basch E, Potosky AL, Roberts AC, Loeffler DR, Reeve BB (2014) Review of electronic patient-reported outcomes systems used in cancer clinical care. J Oncol Pract 10:e215–e222CrossRef

18.

Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, Rogak L, Bennett AV, Dueck AC, Atkinson TM, Chou JF, Dulko D, Sit L, Barz A, Novotny P, Fruscione M, Sloan JA, Schrag D (2016) Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol 34:557–565CrossRef

19.

Basch E, Deal AM, Dueck AC, Scher HI, Kris MG, Hudis C, Schrag D (2017) Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA 318:197–198CrossRef

20.

Krishna S, Boren SA, Balas EA (2009) Healthcare via cell phones: a systematic review. Telemed J E Health 15:231–240CrossRef

21.

Free C, Phillips G, Watson L, Galli L, Felix L, Edwards P, Patel V, Haines A (2013) The effectiveness of mobile-health technologies to improve health care service delivery processes: a systematic review and meta-analysis. PLoS Med 10:e1001363CrossRef

22.

McCann L, Maguire R, Miller M, Kearney N (2009) Patients’ perceptions and experiences of using a mobile phone-based advanced symptom management system (ASyMS) to monitor and manage chemotherapy related toxicity. Eur J Cancer Care (Engl) 18:156–164CrossRef

23.

Maguire R, McCann L, Miller M, Kearney N (2008) Nurse’s perceptions and experiences of using of a mobile-phone-based Advanced Symptom Management System (ASyMS) to monitor and manage chemotherapy-related toxicity. Eur J Oncol Nurs 12:380–386CrossRef

24.

Waki K, Fujita H, Uchimura Y, Omae K, Aramaki E, Kato S, Lee H, Kobayashi H, Kadowaki T, Ohe K (2014) DialBetics: a novel smartphone-based self-management support system for type 2 diabetes patients. J Diabetes Sci Technol 8:209–215CrossRef

25.

Parati G, Torlasco C, Omboni S, Pellegrini D (2017) Smartphone applications for hypertension management: a potential game-changer that needs more control. Curr Hypertens Rep 19:48CrossRef

26.

Nguyen HH, Silva JN (2016) Use of smartphone technology in cardiology. Trends Cardiovasc Med 26:376–386CrossRef

27.

Shin DW, Park JH, Shim EJ, Hahm MI, Park JH, Park EC (2012) Predictors and outcomes of feeling of insufficient consultation time in cancer care in Korea: results of a nationwide multicenter survey. Support Care Cancer 20:1965–1973CrossRef

Title: Feasibility and accessibility of electronic patient-reported outcome measures using a smartphone during routine chemotherapy: a pilot study
Authors: Woo Kyun Bae
Jihyun Kwon
Hyun Woo Lee
Sang-Cheol Lee
Eun-Kee Song
Hyeok Shim
Keun Ho Ryu
Jemin Song
Sungbo Seo
Yaewon Yang
Jong-Hyock Park
Ki Hyeong Lee
Hye Sook Han
Publication date: 01-11-2018
Publisher: Springer Berlin Heidelberg
Published in: Supportive Care in Cancer / Issue 11/2018
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-018-4232-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 11/2018

A pragmatic comparative study of palliative care clinician’s reports of the degree of shadowing visible on plain abdominal radiographs

Japanese physicians’ attitudes toward end-of-life discussion with pediatric patients with cancer

Development of a simplified multivariable model to predict neutropenic complications in cancer patients undergoing chemotherapy

Matrix metalloproteinase expression is altered in the small and large intestine following fractionated radiation in vivo

Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial

Awareness of dysgeusia and gustatory tests in patients undergoing chemotherapy for breast cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer